ArticleCureus2026
Prevalence, Demographic Distribution, and Antimicrobial Resistance Patterns of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Urinary Tract Infections: A Cross-Sectional Study in a Tertiary Care Hospital in Manipur, India.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUrinary tract infections (UTIs) are among the most common bacterial infections globally, with
objectivesThis cross-sectional study aimed to determine the prevalence of ESBL-producing
methodsFrom September 2015 to August 2017, 230 non-repetitive
resultsOf the 230 isolates, 171 (74.3%) were screened positive and 97 (56.7%) were confirmed as ESBL producers by CDT. Female patients predominated with 185 (80.4%) cases; the male-to-female ratio was 1:4.1, with the highest prevalence in the 16-25 years age group, accounting for 44 (19.1%) cases. Community-acquired isolates represented 172 (74.8%) cases, with 68 (70.1%) showing ESBL positivity versus 29 (29.9%) in inpatient isolates. All isolates retained 100% sensitivity to imipenem. ESBL producers exhibited complete resistance to cefpodoxime, 7 (7.2%) to gentamicin, and high co-resistance to ciprofloxacin. Non-producers showed significantly lower resistance rates (p < 0.05).
conclusionsThis study demonstrates a high prevalence of ESBL-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.